LVAD surgery is an open-heart procedure that implants a mechanical pump inside your chest to help a failing left ventricle push blood to the rest of your body. The device doesn’t replace the heart. Instead, it takes over most of the pumping work that the weakened left side can no longer do on its own. Today, the only FDA-approved LVAD on the market is the HeartMate 3, a third-generation centrifugal-flow pump that received U.S. approval in 2017.
Why an LVAD Is Implanted
LVADs are reserved for people with advanced heart failure who haven’t improved with medication, cardiac devices, or other standard treatments. Candidates typically have a heart that pumps less than 25% of the blood it should with each beat (a normal heart ejects about 55% or more) and have been living with the most severe level of heart failure symptoms for at least 60 to 90 days despite maximum treatment.
The device serves one of two purposes. For patients who are eligible for a heart transplant, the LVAD acts as a “bridge to transplant,” keeping them alive and functional while they wait for a donor heart. For those who aren’t transplant candidates, whether because of age, other health conditions, or personal choice, the LVAD is implanted as permanent “destination therapy,” meaning the pump is their long-term treatment rather than a stopgap.
How the Surgery Works
The operation is performed through a median sternotomy, a vertical incision down the center of the chest that splits the breastbone. With the chest open, the surgeon identifies the apex of the left ventricle, the muscular bottom tip of the heart. A circular core of tissue is removed from the apex, and the pump’s inflow tube is inserted into that opening. Blood flows from the ventricle into the pump.
From the pump, an outflow tube called a graft is stitched to the ascending aorta, the large artery that carries blood out to the body. Once connected, blood moves from the left ventricle into the device, gets pushed through the graft, and enters the aorta, effectively bypassing the weakened heart muscle. A thin cable called a driveline tunnels from the pump through the abdominal wall and exits through a small hole in the skin. This cable connects to an external controller and batteries that power the device.
Recovery After Implantation
Most patients spend four to five days in the ICU immediately after surgery while intravenous medications are gradually reduced. The total hospital stay averages 14 to 21 days, during which the medical team monitors device function, manages pain, and begins rehabilitation. Before discharge, patients and their caregivers go through extensive training on how to care for the driveline exit site, swap batteries, respond to alarms, and manage daily activities with the equipment.
The functional improvement can be dramatic. About 80% of LVAD patients achieve a quality of life comparable to people with mild or no heart failure symptoms within two years of implantation, and those benefits hold steady through at least five years of support. People who could barely walk across a room before surgery often return to cooking, light exercise, and social activities.
Survival Rates
With the current generation HeartMate 3, one-year survival sits around 85%, and two-year survival around 80%. Those numbers represent a significant leap over earlier pump designs. The HeartMate 3’s full-magnetic levitation system reduces friction and blood damage inside the pump, which has cut rates of clot formation and stroke compared to its predecessors. An older competing device, the HeartWare HVAD, was pulled from the market in June 2021 because of technical problems and inferior outcomes relative to the HeartMate 3.
Risks and Complications
The driveline, the cable that exits through the skin, is the most persistent source of trouble. Because it creates a permanent opening in the body, it’s vulnerable to infection. Across studies, driveline infection rates average about 8%, with roughly 9% of infections occurring within the first three months after implantation. These infections range from mild skin irritation at the exit site to serious bloodstream infections that can lead to hospitalization.
Other notable risks include gastrointestinal bleeding, which happens partly because patients take blood thinners to prevent clots from forming inside the pump. Stroke is another concern, both from blood clots and from bleeding in the brain. Pump thrombosis, where a clot forms inside the device itself, has become less common with the HeartMate 3 but hasn’t been eliminated entirely. Right heart failure can also develop after surgery, since the LVAD only assists the left side and may unmask weakness on the right.
Daily Life With an LVAD
Living with an LVAD means being physically tethered to external equipment at all times. The controller, roughly the size of a small tablet, monitors pump speed and alerts you to problems. Two batteries power the system and typically need to be swapped out every several hours when you’re away from a wall outlet. At home, most people plug the controller directly into an AC power source overnight.
Showering requires a specific routine. The controller and batteries go into a waterproof shower bag that hangs around your neck for the entire duration, positioned on the same side of your body as the driveline exit to prevent pulling. Before stepping into the water, the driveline site must be covered with a waterproof barrier like Aquaguard or Press-n-Seal, sealed with medical tape on all edges while lying down or reclining so the skin stays flat and gap-free. The shower stream should never be pointed directly at the driveline covering.
Swimming and submerging in water (baths, pools, hot tubs) are off-limits because of the infection risk at the driveline site. Contact sports are also restricted. But many patients drive, travel, return to work, and exercise at moderate intensity. The daily reality involves checking equipment, caring for the driveline exit site with sterile dressing changes, and carrying backup batteries whenever you leave the house.
Cost of the Procedure
LVAD implantation is one of the most expensive inpatient procedures in the United States. Medicare payments for the implant hospitalization average roughly $177,000 and can range from about $123,000 to over $271,000 depending on the hospital and the complexity of the case. That figure covers the initial surgery and hospital stay but not the ongoing costs of follow-up care, medications, and equipment maintenance. Medicare expanded its coverage criteria for LVADs in 2013, broadening both the types of patients eligible for reimbursement and the number of centers qualified to perform the implant. Most private insurers also cover LVAD therapy for patients who meet clinical criteria, though pre-authorization is typically required.